Title:
FUSION PROTEIN OF ANTI-TIGIT ANTIBODY AND IL2 OR VARIANT THEREOF, AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/222035
Kind Code:
A1
Abstract:
The present disclosure provides a fusion protein of an anti-TIGIT antibody and IL2, a variant thereof, and an application thereof. Specifically, the present disclosure provides a fusion protein, comprising: (a) a first polypeptide, which comprises an anti-TIGIT antibody or an antigen-binding fragment thereof; (b) a second polypeptide, which comprises interleukin-2 (IL-2) or a variant thereof having lymphocyte growth promoting activity. The second polypeptide is fused to the first polypeptide. The disclosure also provides an application of the fusion protein in the positive regulation of immune cell activity and/or improvement of immune response, and/or an application for treating cancer, immunodeficiency diseases or inflammatory diseases, or infectious diseases.
Inventors:
CHEN YI (CN)
CAI ZELING (CN)
HE QIAOQIAO (CN)
WANG YALING (CN)
CAI ZELING (CN)
HE QIAOQIAO (CN)
WANG YALING (CN)
Application Number:
PCT/CN2023/094778
Publication Date:
November 23, 2023
Filing Date:
May 17, 2023
Export Citation:
Assignee:
SHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K19/00; A61K38/20; A61K39/395; A61K47/68; A61P35/00; C07K14/55; C07K16/28; C07K16/30; C12N15/13; C12N15/62
Domestic Patent References:
| WO2023045361A1 | 2023-03-30 | |||
| WO2020249003A1 | 2020-12-17 |
Foreign References:
| CN115838424A | 2023-03-24 | |||
| CN110505883A | 2019-11-26 | |||
| CN112368015A | 2021-02-12 | |||
| CN110997720A | 2020-04-10 | |||
| US11028172B1 | 2021-06-08 |
Attorney, Agent or Firm:
SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC (CN)
Download PDF: